EGFR and prostate cancer: Specifically, the postoperative pathological stage of lung adenocarcinoma was pT1N2M0 with an EGFR exon 19 deletion mutation, while the prostate cancer was complicated by multiple metastases to the lungs, lymph nodes, and bones.